- Home
- MRCC vs ACHV Comparison
MRCC vs ACHV Comparison
Compare MRCC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRCC | ACHV |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.8M | 233.2M |
| IPO Year | 2011 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MRCC | ACHV |
|---|---|---|
| Price | $4.70 | $3.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 149.4K | ★ 322.2K |
| Earning Date | 03-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 7.84% | N/A |
| EPS Growth | N/A | ★ 17.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.11 | $1.84 |
| 52 Week High | $7.92 | $6.03 |
Technical Indicators
Market Signals| Indicator | MRCC | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 37.71 | 25.26 |
| Support Level | $4.11 | $3.03 |
| Resistance Level | $6.77 | $3.39 |
| Average True Range (ATR) | 0.24 | 0.23 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 66.28 | 4.27 |
Price Performance
Historical ComparisonAbout MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.